Mitsubishi UFJ Asset Management Co. Ltd. Has $9.57 Million Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 13.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 143,145 shares of the biotechnology company's stock after purchasing an additional 16,471 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. owned approximately 0.08% of BioMarin Pharmaceutical worth $9,566,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the stock. Oregon Public Employees Retirement Fund increased its stake in shares of BioMarin Pharmaceutical by 0.4% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 38,738 shares of the biotechnology company's stock valued at $2,546,000 after acquiring an additional 164 shares during the period. Fifth Third Bancorp grew its holdings in shares of BioMarin Pharmaceutical by 13.9% during the fourth quarter. Fifth Third Bancorp now owns 1,351 shares of the biotechnology company's stock valued at $89,000 after buying an additional 165 shares in the last quarter. TD Private Client Wealth LLC raised its position in BioMarin Pharmaceutical by 57.4% during the third quarter. TD Private Client Wealth LLC now owns 510 shares of the biotechnology company's stock valued at $36,000 after buying an additional 186 shares during the period. First Hawaiian Bank lifted its stake in BioMarin Pharmaceutical by 1.4% in the 4th quarter. First Hawaiian Bank now owns 14,700 shares of the biotechnology company's stock worth $966,000 after acquiring an additional 200 shares in the last quarter. Finally, Blue Trust Inc. boosted its position in BioMarin Pharmaceutical by 27.5% during the 4th quarter. Blue Trust Inc. now owns 1,095 shares of the biotechnology company's stock worth $77,000 after acquiring an additional 236 shares during the period. Institutional investors and hedge funds own 98.71% of the company's stock.

Remove Ads

BioMarin Pharmaceutical Stock Performance

Shares of BMRN stock traded down $6.27 during mid-day trading on Friday, reaching $61.22. The stock had a trading volume of 1,722,740 shares, compared to its average volume of 1,848,090. The firm has a market cap of $11.68 billion, a PE ratio of 27.82, a P/E/G ratio of 0.61 and a beta of 0.30. BioMarin Pharmaceutical Inc. has a one year low of $60.63 and a one year high of $94.85. The firm's 50 day simple moving average is $67.98 and its 200 day simple moving average is $67.31. The company has a quick ratio of 2.62, a current ratio of 5.33 and a debt-to-equity ratio of 0.11.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last issued its quarterly earnings data on Wednesday, February 19th. The biotechnology company reported $0.72 EPS for the quarter, topping analysts' consensus estimates of $0.54 by $0.18. The firm had revenue of $747.31 million for the quarter, compared to analyst estimates of $711.05 million. BioMarin Pharmaceutical had a net margin of 14.96% and a return on equity of 9.91%. On average, analysts forecast that BioMarin Pharmaceutical Inc. will post 3.15 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms recently commented on BMRN. UBS Group raised their price target on shares of BioMarin Pharmaceutical from $109.00 to $113.00 and gave the stock a "buy" rating in a report on Thursday, February 20th. Citigroup lifted their price objective on BioMarin Pharmaceutical from $81.00 to $82.00 and gave the company a "neutral" rating in a research report on Thursday, February 20th. Oppenheimer raised BioMarin Pharmaceutical from a "market perform" rating to an "outperform" rating and set a $98.00 target price on the stock in a research report on Monday, February 24th. Cantor Fitzgerald reiterated an "overweight" rating and set a $90.00 price target on shares of BioMarin Pharmaceutical in a report on Thursday, February 20th. Finally, Scotiabank raised their price objective on shares of BioMarin Pharmaceutical from $78.00 to $80.00 and gave the company a "sector perform" rating in a research report on Thursday, February 20th. Seven research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $94.00.

Insider Activity

In other BioMarin Pharmaceutical news, CAO Erin Burkhart sold 1,344 shares of the company's stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $68.38, for a total transaction of $91,902.72. Following the transaction, the chief accounting officer now directly owns 13,105 shares in the company, valued at approximately $896,119.90. This represents a 9.30 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 1.85% of the stock is currently owned by insiders.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.